Thermo Fisher Bioproduction Insights

  1. Aiming For Success In Early mAb Process Development And Beyond 7/15/2025

    Developing a monoclonal antibody (mAb) requires strict quality compliance. Building on a strong foundation from the start with a quality by design (QbD) approach is key for success and minimizing variability.

  2. Enabling Development Of Scalable, Personalized Cell Therapies For Solid Tumor Treatments 6/16/2025

    Harnessing the body’s own immune system, researchers are developing personalized cell therapies to target solid tumors, using a patient’s unique mutations to create powerful, individualized treatments.

  3. Manufacturing CAR T Cell Therapies: Challenges, Insights And Solutions 6/16/2025

    Manufacturing patient-specific cell therapies is a complex, multi-step process. Addressing key hurdles in production time, scalability, and cost is crucial to making these vital treatments more accessible.

  4. Raw Material Considerations For Cell Therapies 6/16/2025

    For cell therapy developers, selecting appropriate raw materials is a significant challenge. Examine key considerations for mitigating risk and aligning with current regulatory expectations.

  5. Next-Gen Biomanufacturing: Process Intensification For mAb Production 6/13/2025

    Intensified processes, omics-driven media, and advanced bioreactors can boost efficiency and scalability in mAb production.

  6. Comparing Serum-free To Serum-Supplemented Media 6/9/2025

    Reducing serum in vaccine manufacturing is a key consideration for lowering costs and improving supply security. We compare performance in serum-free versus serum-supplemented media.

  7. A Temperature-Stable Replacement For Animal Trypsin In Cell Dissociation Applications 6/9/2025

    Improve cell dissociation with a gentle, recombinant enzyme. This temperature-stable protease shows dissociation kinetics similar to porcine trypsin but with lower cell toxicity and greater overall purity.

  8. Exploring The Challenges Of Cell Dissociation In Vaccine Manufacturing 6/9/2025

    Vaccine manufacturing relies on efficient cell dissociation methods. Explore the challenges of traditional approaches like trypsin and the benefits of animal origin-free alternatives for improved workflows.

  9. Master The Course In Cell Culture 6/9/2025

    Learn how to navigate the complexities of mAb production with actionable strategies for quality-driven processes, supplier selection, and future-proofing your biologic manufacturing systems.

  10. Streamline Your mAb Manufacturing With Strategic Development And CDMO Compatibility 6/4/2025

    Though the journey to mAb development begins at lab scale, for clinical trials and commercial distribution, a production process must be streamlined and scalable to 2,000 L production and above.